Maxence Wisztorski
-
Associate Professor
Dr. Maxence Wisztorski is a Senior Associate Professor (Maître de Conférences Hors Classe) at the University of Lille, where he has held a permanent position since September 2007 within the PRISM Laboratory (Inserm Unit 1192). He is a specialist in proteomics, mass spectrometry and spatial biology. From 2016 to 2022, he served as the Assistant Director of the Clic-Imaging core facility, now known as MS4Omics, at the University of Lille. In 2022, he was promoted to the rank of Senior Associate Professor (Maître de Conférences Hors Classe) through the national quota. He is now member of the group PRODIGY (Protein dynamic and functional interactions in human pathophysiology). Currently, he is developing innovative methods to study protein-protein interactions and their roles in disease progression. His research emphasizes translating laboratory discoveries into clinical applications, creating tools and insights that have a significant impact on patient care and diagnostic accuracy.
Dr. Wisztorski has authored over 61 scientific publications (2006-2024), addressing topics such as fallopian tube lesions as potential precursors of ovarian cancer and the spatial analysis of the glioblastoma proteome. He was first or co-first author on 13 publications and the corresponding or last author on 8. Notably, parts of Dr. Wisztorski’s developments have led to the creation of groundbreaking methodologies, one of which was recognized this year as the “Method of the Year” by Nature Methods (Spatial Proteomics).
Dr. Maxence Wisztorski’s expertise has been recognized through several prestigious appointments, including his nomination as a member of the National Committee of Universities (CNU) Section 68 since 2019 and his election as a board member of this committee starting in 2024. He is frequently called upon as an expert by regional and NAtional agencies, and international institutions such as F.R.S.-FNRS and FRIA in Belgium. He is an active member of the academic community. From 2016 to 2019, he served on the Board of the French Society of Mass Spectrometry. In 2024, he was one of the main organizers of the SMAP (Mass Spectrometry Applied to Proteomics) conference in Lille, which brought together 480 national and international participants.
As part of his editorial contributions, Dr. Wisztorski serves as an associate editor for the Journal of Integrated -OMICS, Applied Sciences and Frontiers in Oncology and regularly reviews manuscripts for high-impact journals journals.
Below is a list of the 10 most significant publications and patents from the past decade, along with a brief description of the impact of each work on policies or practices in biology and health.
1. “Fallopian tube lesions as potential precursors of early ovarian cancer: a comprehensive proteomic analysis” Wisztorski M., Aboulouard S., Roussel L., Duhamel M., Saudemont P., Cardon T., Narducci F., Robin Y-M., Lemaire A-S., Bertin D., Hajjaji N., Kobeissy F., Leblanc E., Fournier I., Salzet M. Cell Death Dis. 2023 Sep 30;14(9):644. doi: 10.1038/s41419-023-06165-5.
Impact: This study identifies molecular markers in pre-neoplastic fallopian tube lesions that confirm their role as precursors of ovarian cancer, influencing strategies for early detection and prevention.
2. “Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival” Duhamel M.*, Drelich L.*, Wisztorski M*., Aboulouard S., Gimeno J.P., Ogrinc N., Devos P., Cardon T., Weller M., Escande F., Zairi F., Maurage C-A., Le Rhun É., Fournier I., Salzet M.Nat Commun. 2022 Nov 4;13(1):6665. doi: 10.1038/s41467-022-34208-6.
Impact: Offers a comprehensive proteomic characterization of glioblastoma, identifying molecular signatures that can guide patient stratification and improve personalized treatment strategies.
3. “Toward High Spatially Resolved Proteomics Using Expansion Microscopy”Drelich L., Aboulouard S., Franck J., Salzet M., Fournier I., Wisztorski M. Anal Chem. 2021 Sep 14;93(36):12195-12203. doi: 10.1021/acs.analchem.0c05372.
Impact: Describes the adaptation of expansion microscopy for proteomics, enabling high-resolution spatial analysis of tissues, a significant advancement for studying complex pathologies.
4. “In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer” Aboulouard S.*, Wisztorski M.*, Duhamel M., Saudemont P., Cardon T., Narducci F., Lemaire A-S., Kobeissy F., Leblanc E., Fournier I., Salzet M.Cell Rep Med. 2021 Jun 15;2(6):100318. doi: 10.1016/j.xcrm.2021.100318.
Impact: Reveals protein variations in sentinel lymph nodes across different grades of endometrial cancer, improving prognostic evaluation and patient stratification.
5. “Cumulative learning enables convolutional neural network representations for small mass spectrometry data classification”Seddiki K., Saudemont P., Precioso F., Ogrinc N., Wisztorski M., Salzet M., Fournier I., Droit A.Nat Commun. 2020 Nov 5;11(1):5595. doi: 10.1038/s41467-020-19354-z. Impact: Introduces cumulative learning methods for convolutional neural networks, improving classification of small datasets, particularly mass spectrometry data in clinical applications.
6. “Mechanisms of innate events during skin reaction following intradermal injection of seasonal influenza vaccine”Gonnet J., Poncelet L., Meriaux C., Gonçalves E., Weiss L., Tchitchek N., Pedruzzi E., Soria A., Boccara D., Vogt A., Bonduelle O., Hamm G., Ait-Belkacem R., Stauber J., Fournier I., Wisztorski M.*, Combadiere B*. J Proteomics. 2020 Mar 30;216:103670. doi: 10.1016/j.jprot.2020.103670.
Impact: Identifies early molecular biomarkers of skin immune response post-vaccination, advancing immunization strategies and vaccine design.
7. “Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification” Le Rhun E.*, Duhamel M.*, Wisztorski M.*, Gimeno J.P., Zairi F., Escande F., Reyns N., Kobeissy F., Maurage C-A., Salzet M., Fournier I. Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):875-890. doi: 10.1016/j.bbapap.2016.11.012.
Impact: Demonstrates the utility of MALDI MSI and microproteomics in glioma classification, contributing to more precise and non-invasive diagnostic methods.
8. “Droplet-Based Liquid Extraction for Spatially-Resolved Microproteomics Analysis of Tissue Sections” Wisztorski M., Quanico J., Franck J., Fatou B., Salzet M., Fournier I. Methods Mol Biol. 2017;1618:49-63. doi: 10.1007/978-1-4939-7051-3_6.
Impact: Introduces spatially-resolved liquid extraction for microproteomics, enhancing the study of tumor microenvironments and tissue heterogeneity.
9. “Spatially-resolved protein surface microsampling from tissue sections using liquid extraction surface analysis” Wisztorski M., Desmons A., Quanico J., Fatou B., Gimeno J.P., Franck J., Salzet M., Fournier I. Proteomics. 2016 Jun;16(11-12):1622-32. doi: 10.1002/pmic.201500508.
Impact: Develops a microsampling method for high-resolution proteomics of tissue microenvironments, advancing molecular pathology.
10. “In vivo Real-Time Mass Spectrometry for Guided Surgery Application”Fatou B., Saudemont P., Leblanc E., Vinatier D., Mesdag V., Wisztorski M., Focsa C., Salzet M., Ziskind M., Fournier I.Sci Rep. 2016 May 18;6:25919. doi: 10.1038/srep25919.
Impact: Introduces SpiderMass, a real-time mass spectrometry system for guided surgery, significantly improving cancer surgery precision.